SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 160 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $30,407,799 | +17.7% | 2,094,201 | +69.6% | 0.09% | +15.6% |
Q2 2023 | $25,844,364 | +133.4% | 1,234,800 | +135.5% | 0.08% | +126.5% |
Q1 2023 | $11,075,328 | -52.9% | 524,400 | -43.2% | 0.03% | -57.5% |
Q4 2022 | $23,500,530 | +275.6% | 923,400 | +156.5% | 0.08% | +220.0% |
Q1 2022 | $6,257,000 | -19.0% | 360,000 | +2.0% | 0.02% | -19.4% |
Q4 2021 | $7,729,000 | -12.3% | 353,100 | -23.4% | 0.03% | -20.5% |
Q3 2021 | $8,808,000 | +64.2% | 460,900 | +47.5% | 0.04% | +62.5% |
Q2 2021 | $5,364,000 | -74.7% | 312,400 | -67.0% | 0.02% | -75.8% |
Q1 2021 | $21,170,000 | -16.8% | 946,800 | -17.2% | 0.10% | -20.2% |
Q4 2020 | $25,440,000 | +937.9% | 1,143,900 | +588.9% | 0.12% | +853.8% |
Q3 2020 | $2,451,000 | +78.4% | 166,037 | -2.3% | 0.01% | +116.7% |
Q3 2018 | $1,374,000 | -67.8% | 170,000 | -43.3% | 0.01% | -66.7% |
Q1 2018 | $4,269,000 | +214.4% | 300,000 | +203.0% | 0.02% | +125.0% |
Q1 2017 | $1,358,000 | – | 99,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |